GHP NewsLatest Science Literature update ViVa week 16-2026 1. MF59-aQIV looks economically persuasive in Korea and Taiwan — but the price assumptions do a lot of the work This modelling study assessed the cost-effectiveness of MF59-adjuvanted quadrivalent influenza vaccine... 22 April, 202623 min read